The past, present, and future of breast cancer models for nanomedicine development

Fecha de publicación: 01/06/2021 Fecha Ahead of Print: 01/04/2021

Autores de CIPF

• Paz Boix Montesinos

  Autor

• 

  Paula Soriano Teruel

  Autor

• 

  Ana Armiñan De Benito

  Autor

• 

  Maria Mar Orzáez Calatayud

  Autor

• 

  Maria Jesus Vicent Docon

  Autor

Grupos de Investigación

• Laboratorio de Polímeros Terapéuticos

  

  Jefe/a de Grupo

  Maria Jesus Vicent Docon

• Laboratorio de Terapias Dirigidas en Cáncer e Inflamación

  

  Jefe/a de Grupo

  Maria Mar Orzáez Calatayud

Abstract

Even given recent advances in nanomedicine development of breast cancer treatment in recent years and promising results in pre-clinical models, cancer nanomedicines often fail at the clinical trial stage. Limitations of conventional in vitro models include the lack of representation of the stromal population, the absence of a three-dimensional (3D) structure, and a poor representation of inter-tumor and intratumor heterogeneity. Herein, we review those cell culture strategies that aim to overcome these limitations, including cell co-cultures, advanced 3D cell cultures, patient-derived cells, bioprinting, and microfluidics systems. The in vivo evaluation of nanomedicines must consider critical parameters that include the enhanced permeability and retention effect, the host's immune status, and the site of tumor implantation. Here, we critically discuss the advantages and limitations of current in vivo models and report how the improved selection and application of breast cancer models can improve the clinical translation of nanomedicines. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords

• Breast cancer; Metastasis; Pre-clinical models; Nanomedicines; Organoids; Patient-derived xenografts; Animal models; Biomarkers